Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit

NDT Plus

Volumn 2, Issue 6, 2009, Pages 439-447

  Davenport, Andrew ^a   Tolwani, Ashita ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

Author keywords

anticoagulation; citrate; CRRT; haemodialysis; haemofiltration

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; ARGATROBAN; BICARBONATE; CALCIUM; CALCIUM CHLORIDE; CALCIUM ION; CHELATING AGENT; CHLORIDE; CITRATE CALCIUM; CITRATE TRISODIUM; CITRIC ACID; GLUCONATE CALCIUM; HEPARIN; HEPARINOID; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; NAFAMSTAT; POTASSIUM; PRISMOCITRATE; PROSTANOID; PROTAMINE; SODIUM; UNCLASSIFIED DRUG;

ACID BASE BALANCE; ANTICOAGULATION; BIOCOMPATIBILITY; BLEEDING; BLOOD GAS; BLOOD TRANSFUSION; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DIALYSATE; DISEASE ASSOCIATION; DRUG METABOLISM; ELECTROLYTE BALANCE; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOFILTRATION; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HUMAN; HYPERCALCEMIA; HYPERCOAGULABILITY; HYPERNATREMIA; HYPOCALCEMIA; HYPONATREMIA; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; KIDNEY INJURY; MAGNESIUM METABOLISM; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SODIUM BALANCE; SYSTEMIC CIRCULATION; THROMBOCYTE;

EID: 77955959650     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp136     Document Type: Review

References (42)

1. Sakariassen KS, Ottenhof-RoversM, Sixma JJ. FactorVIII-vonWillebrand factor requires calcium for facilitation of platelet adherence. Blood 1984; 63: 996-1003
2. Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for haemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308: 258-261
3. Flanagan MJ, Pillsbury L, Sadewasser G et al. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kid Dis 1996; 27: 519-524
4. Bos JC, Grooteman MP, van Houte AJ et al. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387-1393
5. Davenport A, Mehta S. The Acute Dialysis Quality Initiative-part VI: access and anticoagulation in CRRT. Adv Ren Replace Ther 2002; 9: 273-281
6. Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib Nephrol 2004; 144: 228-238
7. Tolwani AJ, Prendergast MB, Speer RR et al. A practical citrate anticoagulation continuous venovenous haemodiafiltration protocol formetabolic control and high solute clearance. Clin J AmSoc Nephrol 2006; 1: 79-87
8. Davenport A, Bouman C, Kirpalani A et al. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol 2008; 3: 869-875
9. Mehta RL, McDonald BR, AguilarMMet al. Regional citrate anticoagulation for continuous arteriovenous haemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
10. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55: 1991-1997
11. Kutsogiannis DJ, Mayers I, Chin WD et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration. Am J Kidney Dis 2000; 35: 802-811
12. Dorval M, Madore F, Courteau S et al. A novel citrate anticoagulation regimen for continuous venovenous haemodiafiltration. Intensive Care Med 2003; 29: 1186-1189
13. Gibney N, Cerda J, Davenport A et al. Volume management by renal replacement therapy in acute kidney injury. Int J Artif Organs 2008; 31: 145-155
14. Monchi M, Berghmans D, Ledoux D et al. Citrate versus heparin for anticoagulation in continuous venovenous haemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265
15. Cassina T, Mauri R, Engeler A et al. Continuous veno-venous hemofiltration with regional citrate anticoagulation: a four-year single-center experience. Int J Artif Organs 2008; 31: 937-943
16. TolwaniAJ, Campbell RC, SchenkMBet al. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60: 370-374
17. Swartz R, Pasko D, O'Toole J et al. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61: 134-143
18. Mitchell A, Daul AE, Beiderlinden M et al. A new system for regional citrate anticoagulation in continuous venovenous haemodialysis (CVVHD). Clin Nephrol 2003; 59: 106-114
19. Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous haemodiafiltration using calciumcontaining dialysate. Am J Kidney Dis 2004; 43: 67-73
20. Buturovic-Ponikvar J, Gubensek J, Ponikvar R. Citrate anticoagulation for postdilutional online haemodiafiltration with calcium-containing dialysate and infusate: significant clotting in the venous bubble trap. Int J Artif Organs 2008; 31: 323-428
21. Gabutti L, Marone C, Colucci G et al. Citrate anticoagulation in continuous venovenous haemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-1425
22. Forsythe RM, Wessel CB, Billiar TR et al. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev 2008; 4: CD006163
23. Davenport A. Dialysate and substitution fluids for patients treated by continuous forms of renal replacement therapy. Contrib Nephrol 2001; 132: 313-322
24. Davenport A. Replacement and dialysate fluids for patients with acute renal failure treated by continuous veno-venous haemofiltration and/or haemodiafiltration. Contrib Nephrol 2004; 144: 317-328
25. Kramer L, Bauer E, Joukhadar C et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455
26. Davenport A, Will EJ, Davison AM. Paradoxical increase in arterial hydrogen ion concentration in patients with hepato-renal failure given lactate based fluids. Nephrol Dial Transplant 1990; 5: 432-436
27. Nowak MA, Campbell TE. Profound hypercalcemia in continuous veno-venous haemofiltration dialysis with trisodium citrate anticoagulation and hepatic failure. Clin Chem 1997; 43: 412-413
28. Meier-Kriesche HU, Gitomer J, Kinkel K et al. Increased total to ionised calcium ratio during continuous venovenous haemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752
29. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate anticoagulation. Am J Kidney Dis 1987; 9: 235-236
30. Morgera S, Scholle C, Voss G et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous haemodialysis: single-center experience. Nephron Clin Pract 2004; 97: c131-c136
31. Davenport A, Worth DP, Will EJ. Hypochloraemic alkalosis after high-flux continuous haemofiltration and continuous arteriovenous haemofiltration with dialysis. Lancet 1988; 8586: 658
32. Cointault O, Kamar N, Bories P et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19: 171-178
33. Kindgen-Milles D, Amman J, Kleinekofort W et al. Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Int J Artif Organs 2008; 31: 363-366
34. Davenport A. Potential adverse effects of replacing high volume haemofiltration exchanges on electrolyte balance and acid-base status using the current commercially available replacement solutions in patients with acute renal failure. Int J Artif Organs 2008; 31: 3-5
35. Charney DI, Salmond R. Cardiac arrest after hypertonic citrate anticoagulation for chronic haemodialysis. ASAIO Trans 1990; 36: M217-M219
36. Mehta RL, McDonald BR, Ward DM. Membrane transfer of citrate and calcium in regional citrate anticoagulation for continuous arteriovenous hemodialysis. J Am Soc Nephrol 1990; 1: 368
37. Van Der Voort PHJ, Postma SR, Kingma WP et al. An observational study on the effects of nadroparin based and citrate based continuous venovenous haemofiltration on calcium metabolism. Blood Purif 2007; 25: 267-273
38. DavenportA,AultonK, PayneRBet al.Hyperlactataemia and increasing metabolic acidosis in hepatorenal failure treated by haemofiltration. Ren Fail 1990; 12: 99-101
39. Kutsogiannis DJ, Gibney RT, Stollery D et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
40. Oudemans-van Straaten HM, Bosman RJ, Koopmans M et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552
41. DavenportA. The management of Heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 2001; 3: 81-85
42. Davenport A. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis 2009; 54: 361-374